MeSH term
Frequency | Condition_Probility | Humans | 275 | 0.0 |
Animals | 73 | 0.0 |
Cell Line | 58 | 0.0 |
DNA-Binding Proteins/genetics | 2 | 0.0 |
Hamsters | 6 | 0.0 |
Protein Biosynthesis | 7 | 0.0 |
Proto-Oncogene Proteins/genetics | 2 | 0.0 |
Research Support, Non-U.S. Gov't | 185 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 90 | 0.0 |
Transcription, Genetic | 9 | 0.0 |
*Adaptor Proteins, Signal Transducing | 121 | 9.0 |
Amino Acid Chloromethyl Ketones/pharmacology | 7 | 6.0 |
Antigens, CD3/immunology | 2 | 0.0 |
Carrier Proteins/*antagonists & inhibitors | 2 | 8.0 |
Caspases/*antagonists & inhibitors | 3 | 27.0 |
Cell Division/drug effects | 2 | 0.0 |
Cells, Cultured | 30 | 0.0 |
Cysteine Proteinase Inhibitors/pharmacology | 15 | 6.0 |
Enzyme Activation | 52 | 1.0 |
Jurkat Cells | 46 | 3.0 |
MAP Kinase Signaling System | 2 | 0.0 |
Mice | 39 | 0.0 |
Mitogen-Activated Protein Kinase 1/metabolism | 3 | 0.0 |
Mitogen-Activated Protein Kinase 3 | 3 | 0.0 |
p38 Mitogen-Activated Protein Kinases | 6 | 0.0 |
Antigens, CD/physiology | 2 | 0.0 |
Carrier Proteins/*chemistry/metabolism | 4 | 10.0 |
Receptors, Tumor Necrosis Factor/physiology | 5 | 7.0 |
Receptors, Tumor Necrosis Factor, Type I | 20 | 6.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 21 | 0.0 |
Structure-Activity Relationship | 7 | 0.0 |
TNF Receptor-Associated Factor 1 | 24 | 15.0 |
Two-Hybrid System Techniques | 6 | 0.0 |
Base Sequence | 18 | 0.0 |
Cell Line, Transformed | 3 | 0.0 |
DNA, Complementary | 6 | 0.0 |
Apoptosis/drug effects/physiology | 2 | 2.0 |
Down-Regulation/drug effects/physiology | 2 | 5.0 |
Lipopolysaccharides/*pharmacology | 3 | 0.0 |
Male | 30 | 0.0 |
Mice, Inbred C57BL | 2 | 0.0 |
RNA, Messenger/biosynthesis | 2 | 0.0 |
Amino Acid Sequence | 35 | 0.0 |
Apoptosis/*drug effects | 26 | 3.0 |
Cell Nucleus/*metabolism | 3 | 0.0 |
Female | 23 | 0.0 |
Mice, Knockout | 4 | 0.0 |
Molecular Sequence Data | 34 | 0.0 |
Protein p53/metabolism | 2 | 0.0 |
Proteins/chemistry/genetics/*metabolism | 2 | 2.0 |
Receptors, Tumor Necrosis Factor/*metabolism | 15 | 7.0 |
Sequence Alignment | 9 | 0.0 |
Signal Transduction | 41 | 0.0 |
Tumor Cells, Cultured | 68 | 0.0 |
*Tumor Necrosis Factor Receptor-Associated Peptides and Proteins | 5 | 20.0 |
Apoptosis | 25 | 1.0 |
Binding Sites | 13 | 0.0 |
Caspases/metabolism | 63 | 10.0 |
Genetic Complementation Test | 3 | 0.0 |
Hela Cells | 27 | 0.0 |
In Vitro | 3 | 0.0 |
Models, Biological | 16 | 0.0 |
Mutagenesis, Site-Directed | 7 | 0.0 |
Protein Binding | 34 | 0.0 |
Protein Structure, Tertiary | 26 | 0.0 |
Recombinant Proteins/chemistry/genetics/metabolism | 2 | 0.0 |
Antigens, CD95/*genetics | 2 | 7.0 |
Apoptosis/genetics | 2 | 0.0 |
Carrier Proteins/*genetics | 3 | 0.0 |
Caspases/*genetics | 2 | 9.0 |
DNA Primers | 7 | 0.0 |
Antigens, CD95/metabolism | 19 | 13.0 |
Apoptosis/*physiology | 37 | 5.0 |
Carrier Proteins/metabolism | 27 | 3.0 |
Caspases/antagonists & inhibitors/metabolism | 14 | 17.0 |
Cell Survival/physiology | 2 | 1.0 |
Mitochondria/*metabolism | 7 | 4.0 |
NF-kappa B/*metabolism | 11 | 1.0 |
Proto-Oncogene Proteins/metabolism | 9 | 0.0 |
Proto-Oncogene Proteins c-bcl-2/metabolism | 12 | 2.0 |
Antigens, CD95/immunology | 6 | 11.0 |
Breast Neoplasms | 3 | 1.0 |
COS Cells | 4 | 0.0 |
Cloning, Molecular | 19 | 0.0 |
Genetic Vectors | 8 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 15 | 0.0 |
Sequence Homology, Amino Acid | 18 | 0.0 |
Blotting, Western | 32 | 0.0 |
Cell Death | 4 | 1.0 |
Cell Nucleus/metabolism | 6 | 0.0 |
Cell Survival | 7 | 0.0 |
Dose-Response Relationship, Drug | 18 | 0.0 |
Flow Cytometry | 22 | 0.0 |
Membrane Glycoproteins/*metabolism | 5 | 1.0 |
Transfection | 40 | 0.0 |
Tumor Necrosis Factor-alpha/*metabolism | 4 | 0.0 |
Apoptosis/*drug effects/physiology | 9 | 8.0 |
Caspases/*metabolism | 35 | 15.0 |
Proto-Oncogene Proteins c-bcl-2/physiology | 3 | 7.0 |
Pyridines/pharmacology | 3 | 1.0 |
Antigens, CD95/*physiology | 17 | 20.0 |
*Apoptosis | 65 | 4.0 |
B-Lymphocytes/cytology/*immunology | 2 | 2.0 |
Carrier Proteins/*metabolism/physiology | 4 | 19.0 |
Lymphocyte Activation | 5 | 0.0 |
Membrane Potentials | 7 | 3.0 |
Mitochondria/physiology | 3 | 5.0 |
Protein Transport | 6 | 0.0 |
*Signal Transduction | 23 | 1.0 |
Antigens, CD95/*metabolism | 27 | 23.0 |
CHO Cells | 4 | 0.0 |
Carrier Proteins/genetics/metabolism | 5 | 2.0 |
Down-Regulation/drug effects | 3 | 1.0 |
Gene Expression Regulation, Neoplastic/drug effects | 4 | 0.0 |
*Gene Therapy | 3 | 0.0 |
*Intracellular Signaling Peptides and Proteins | 48 | 6.0 |
Membrane Glycoproteins/genetics/metabolism | 2 | 2.0 |
Precipitin Tests | 13 | 0.0 |
Time Factors | 18 | 0.0 |
HL-60 Cells | 4 | 0.0 |
Membrane Glycoproteins/*pharmacology | 8 | 9.0 |
Protein-Tyrosine Kinase/*metabolism | 2 | 0.0 |
Tumor Necrosis Factor-alpha/*pharmacology | 9 | 0.0 |
DNA Fragmentation | 8 | 2.0 |
Enzyme Inhibitors/pharmacology | 19 | 0.0 |
Immunoblotting | 5 | 0.0 |
Ligands | 15 | 0.0 |
Poly(ADP-ribose) Polymerases/metabolism | 5 | 3.0 |
Proteins/metabolism | 21 | 2.0 |
Antibodies/immunology | 2 | 0.0 |
Antigens, CD95/immunology/*physiology | 2 | 16.0 |
Carrier Proteins/*metabolism | 29 | 3.0 |
Cytosol/metabolism | 5 | 0.0 |
Enzyme Precursors/metabolism | 7 | 5.0 |
Macromolecular Substances | 5 | 0.0 |
U937 Cells | 4 | 0.0 |
Antigens, CD95/physiology | 5 | 6.0 |
Carrier Proteins/analysis | 2 | 2.0 |
Microscopy, Fluorescence | 11 | 0.0 |
Sequence Deletion | 6 | 0.0 |
Drug Synergism | 3 | 0.0 |
Interferon Type II/*pharmacology | 3 | 0.0 |
Proteins/*metabolism | 11 | 1.0 |
Carrier Proteins/genetics/*metabolism | 12 | 2.0 |
DNA-Binding Proteins/metabolism | 4 | 0.0 |
Gene Expression | 5 | 0.0 |
*I-kappa B | 2 | 1.0 |
Interleukin-6/biosynthesis | 2 | 0.0 |
Gene Expression Regulation/physiology | 2 | 0.0 |
Proto-Oncogene Proteins/*metabolism | 2 | 0.0 |
Signal Transduction/*physiology | 11 | 0.0 |
Aged | 10 | 0.0 |
Aged, 80 and over | 6 | 0.0 |
Immunohistochemistry | 4 | 0.0 |
Receptors, Tumor Necrosis Factor/metabolism | 17 | 8.0 |
Adenoviridae/genetics | 2 | 0.0 |
Amino Acid Substitution | 2 | 0.0 |
Genes, Reporter | 4 | 0.0 |
Green Fluorescent Proteins | 2 | 0.0 |
Recombinant Proteins/metabolism | 7 | 0.0 |
Adult | 13 | 0.0 |
Antigens, CD95/*immunology | 4 | 11.0 |
Child, Preschool | 5 | 0.0 |
Cycloheximide/pharmacology | 9 | 1.0 |
Membrane Glycoproteins/pharmacology | 7 | 12.0 |
*Proto-Oncogene Proteins c-bcl-2 | 5 | 1.0 |
Tumor Necrosis Factor-alpha/pharmacology | 12 | 1.0 |
*Arabidopsis Proteins | 29 | 35.0 |
Cytochrome c Group/metabolism | 13 | 9.0 |
Electrophoresis, Polyacrylamide Gel | 5 | 0.0 |
Fatty Acid Desaturases/metabolism | 24 | 68.0 |
Mitochondria/metabolism | 10 | 3.0 |
Mitogen-Activated Protein Kinase Kinases/metabolism | 3 | 1.0 |
Transcription Factor AP-1/metabolism | 2 | 0.0 |
Middle Aged | 9 | 0.0 |
Carrier Proteins/*physiology | 9 | 4.0 |
Caspases/*biosynthesis | 2 | 22.0 |
Cytosol/physiology | 2 | 16.0 |
Transcription, Genetic/*physiology | 2 | 1.0 |
Fatty Acid Desaturases/*metabolism | 7 | 77.0 |
*Apoptosis/drug effects | 6 | 5.0 |
Conserved Sequence | 4 | 0.0 |
Mutation/genetics | 4 | 0.0 |
Flavonoids/pharmacology | 2 | 0.0 |
Microscopy, Confocal | 3 | 0.0 |
Mitogen-Activated Protein Kinases/metabolism | 8 | 0.0 |
Phosphorylation | 14 | 0.0 |
Ultraviolet Rays | 3 | 0.0 |
Blotting, Northern | 3 | 0.0 |
DNA/metabolism | 2 | 0.0 |
DNA, Complementary/metabolism | 4 | 0.0 |
Expressed Sequence Tags | 3 | 0.0 |
Plasmids/metabolism | 5 | 0.0 |
RNA, Messenger/metabolism | 9 | 0.0 |
Tissue Distribution | 4 | 0.0 |
Alternative Splicing | 2 | 0.0 |
Enzyme Activation/drug effects | 7 | 0.0 |
JNK Mitogen-Activated Protein Kinases | 12 | 2.0 |
*Protein-Serine-Threonine Kinases | 4 | 0.0 |
TNF Receptor-Associated Factor 2 | 16 | 7.0 |
Comparative Study | 16 | 0.0 |
Gamma Rays | 2 | 0.0 |
Kinetics | 13 | 0.0 |
Caspases/genetics/*metabolism | 2 | 13.0 |
Dimerization | 6 | 0.0 |
Gene Expression Profiling | 2 | 0.0 |
Membrane Glycoproteins/metabolism | 15 | 2.0 |
Tumor Necrosis Factor-alpha/metabolism | 9 | 1.0 |
Antineoplastic Agents, Phytogenic/pharmacology | 3 | 3.0 |
*Nuclear Proteins | 5 | 0.0 |
Paclitaxel/pharmacology | 3 | 3.0 |
Transcription Factors/metabolism | 2 | 0.0 |
Adolescent | 6 | 0.0 |
Antineoplastic Agents/*pharmacology | 8 | 0.0 |
Child | 5 | 0.0 |
Infant | 2 | 0.0 |
Antigens, CD95/genetics | 2 | 8.0 |
Carrier Proteins/biosynthesis | 5 | 8.0 |
Caspases/physiology | 5 | 9.0 |
Membrane Glycoproteins/biosynthesis | 2 | 1.0 |
RNA, Messenger/analysis | 5 | 0.0 |
Coenzyme A Ligases/*genetics | 3 | 33.0 |
Escherichia coli Proteins/*genetics | 2 | 50.0 |
Fibroblasts/metabolism | 3 | 0.0 |
Gene Therapy/*methods | 3 | 0.0 |
Gene Transfer Techniques | 2 | 0.0 |
Luciferases/metabolism | 3 | 0.0 |
Mice, Inbred BALB C | 4 | 0.0 |
Mice, Nude | 2 | 0.0 |
Caspases/biosynthesis/metabolism | 2 | 66.0 |
Down-Regulation | 8 | 0.0 |
Glutathione Transferase/metabolism | 4 | 0.0 |
Oligonucleotides, Antisense/pharmacology | 6 | 2.0 |
Protein Kinase C/metabolism | 2 | 0.0 |
Protein Synthesis Inhibitors/pharmacology | 3 | 0.0 |
Butyrates/pharmacology | 2 | 5.0 |
Enzyme Activation/physiology | 4 | 2.0 |
Jurkat Cells/metabolism | 2 | 9.0 |
Membrane Potentials/physiology | 2 | 2.0 |
Signal Transduction/physiology | 11 | 1.0 |
Antineoplastic Agents/pharmacology | 5 | 0.0 |
Apoptosis/drug effects/*physiology | 13 | 6.0 |
Cisplatin/pharmacology | 3 | 1.0 |
Drug Resistance, Neoplasm | 5 | 0.0 |
Tumor Cells, Cultured/drug effects | 4 | 0.0 |
Antigens, CD95/*biosynthesis | 2 | 11.0 |
Prostatic Neoplasms/drug therapy/*metabolism/pathology | 2 | 33.0 |
Cell Separation | 2 | 0.0 |
Indoles/pharmacology | 2 | 0.0 |
Subcellular Fractions | 2 | 1.0 |
Tetradecanoylphorbol Acetate/pharmacology | 3 | 0.0 |
Protein Binding/drug effects | 2 | 0.0 |
Protein Kinase C/antagonists & inhibitors/metabolism | 2 | 2.0 |
Cyclin D1/genetics | 2 | 3.0 |
Enzyme-Linked Immunosorbent Assay | 2 | 0.0 |
Polymerase Chain Reaction | 7 | 0.0 |
Pregnancy | 3 | 0.0 |
Antigens, CD95/genetics/metabolism | 2 | 28.0 |
Proteins/genetics/metabolism | 3 | 1.0 |
Antigens, CD95/analysis | 2 | 6.0 |
Caspases/analysis | 3 | 15.0 |
Recombinant Proteins/pharmacology | 7 | 0.0 |
Antibodies, Monoclonal/pharmacology | 3 | 0.0 |
*Gene Expression Regulation | 2 | 0.0 |
Membrane Glycoproteins/*physiology | 7 | 2.0 |
Tumor Necrosis Factor-alpha/*physiology | 8 | 2.0 |
Apoptosis/immunology/*physiology | 2 | 25.0 |
Membrane Glycoproteins/genetics/*metabolism | 3 | 1.0 |
Tumor Necrosis Factor-alpha/genetics/*metabolism | 2 | 3.0 |
*Viral Proteins | 11 | 6.0 |
Oligopeptides/pharmacology | 4 | 2.0 |
Up-Regulation/drug effects | 2 | 0.0 |
Gene Expression Regulation | 7 | 0.0 |
*JNK Mitogen-Activated Protein Kinases | 2 | 2.0 |
Proteins/genetics/*metabolism | 4 | 0.0 |
Receptors, Tumor Necrosis Factor/genetics/*metabolism | 2 | 5.0 |
In Situ Nick-End Labeling | 9 | 1.0 |
Up-Regulation | 6 | 0.0 |
Catalysis | 3 | 0.0 |
Arabidopsis Proteins/metabolism | 10 | 71.0 |
Mutation | 9 | 0.0 |
Protein-Serine-Threonine Kinases/metabolism | 3 | 0.0 |
Fatty Acid Desaturases/*physiology | 3 | 100.0 |
Proteins/physiology | 4 | 2.0 |
Doxorubicin/*pharmacology | 2 | 2.0 |
Gene Expression/drug effects | 3 | 0.0 |
Mutagenesis | 3 | 0.0 |
Receptors, Tumor Necrosis Factor/chemistry/genetics/*physiology | 2 | 33.0 |
Apoptosis/physiology | 4 | 1.0 |
Cell Death/*physiology | 4 | 10.0 |
Necrosis | 3 | 0.0 |
T-Lymphocytes/cytology/metabolism | 2 | 7.0 |
Antigens, CD95 | 5 | 12.0 |
Enzyme Inhibitors/metabolism | 2 | 0.0 |
Antigens, CD95/chemistry/*metabolism | 2 | 66.0 |
Models, Molecular | 10 | 0.0 |
Protein Structure, Secondary | 5 | 0.0 |
Fluorescent Antibody Technique | 2 | 0.0 |
Receptors, Tumor Necrosis Factor/*physiology | 7 | 7.0 |
Membrane Glycoproteins/*pharmacology/physiology | 2 | 50.0 |
Tumor Necrosis Factor-alpha/*pharmacology/physiology | 2 | 15.0 |
Antibiotics, Antineoplastic/pharmacology | 3 | 3.0 |
Antigens, CD3/metabolism | 2 | 1.0 |
T-Lymphocytes/cytology/*drug effects | 2 | 13.0 |
Adenosine Triphosphate/metabolism | 2 | 0.0 |
Carrier Proteins | 3 | 5.0 |
Caspases/antagonists & inhibitors/*metabolism | 5 | 9.0 |
Models, Immunological | 2 | 0.0 |
I-kappa B/metabolism | 2 | 2.0 |
Antigens, CD95/metabolism/*physiology | 3 | 50.0 |
*Down-Regulation | 2 | 0.0 |
Oligonucleotides, Antisense/genetics | 2 | 5.0 |
Plasmids | 2 | 0.0 |
Carrier Proteins/genetics | 2 | 0.0 |
*Necrosis | 2 | 13.0 |
Protein Conformation | 3 | 0.0 |
Drug Interactions | 2 | 0.0 |
Mitochondria/*physiology | 2 | 3.0 |
Serpins/pharmacology | 3 | 37.0 |
Cisplatin/*pharmacology | 2 | 1.0 |
Gene Library | 2 | 0.0 |
Organ Specificity | 3 | 0.0 |
Antibodies, Monoclonal/metabolism | 3 | 0.0 |
Antigens, CD/metabolism | 4 | 0.0 |
Cell Death/drug effects/physiology | 2 | 4.0 |
Protein-Serine-Threonine Kinases/*metabolism | 3 | 0.0 |
Tumor Necrosis Factor-alpha/metabolism/pharmacology | 2 | 5.0 |
NF-kappa B/genetics/*metabolism | 2 | 2.0 |
Recombinant Proteins/genetics/metabolism | 3 | 0.0 |
Serpins/metabolism | 7 | 43.0 |
Chromosome Mapping | 2 | 0.0 |
Polymorphism, Single-Stranded Conformational | 2 | 0.0 |
Antigens, CD40/metabolism | 3 | 4.0 |
Apoptosis/*immunology | 3 | 1.0 |
Enzyme Activation/immunology | 4 | 3.0 |
Hydrolysis | 4 | 0.0 |
Signal Transduction/immunology | 4 | 1.0 |
Nuclear Magnetic Resonance, Biomolecular | 3 | 1.0 |
Solutions | 3 | 1.0 |
Carrier Proteins/chemistry/genetics/*metabolism | 4 | 3.0 |
Salts/pharmacology | 2 | 13.0 |
*Signal Transduction/drug effects | 2 | 2.0 |
Tumor Necrosis Factor-alpha/*metabolism/pharmacology | 2 | 4.0 |
3T3 Cells | 3 | 0.0 |
Carrier Proteins/*chemistry/*metabolism | 2 | 4.0 |
*Drosophila Proteins | 2 | 0.0 |
Antigens, CD95/pharmacology | 2 | 50.0 |
Apoptosis/drug effects | 7 | 1.0 |
Cycloheximide/*pharmacology | 2 | 9.0 |
Dactinomycin/*pharmacology | 2 | 14.0 |
Signal Transduction/drug effects | 5 | 0.0 |
Peptide Fragments/metabolism | 4 | 1.0 |
Thermodynamics | 2 | 0.0 |
Receptors, Tumor Necrosis Factor/metabolism/*physiology | 2 | 25.0 |
NF-kappa B/metabolism | 11 | 1.0 |
Cell Line, Tumor | 11 | 0.0 |
Cell Membrane/metabolism | 4 | 0.0 |
Cell-Free System | 2 | 0.0 |
Etoposide/*pharmacology | 2 | 6.0 |
Subcellular Fractions/metabolism | 2 | 0.0 |
Annexin A5/metabolism | 2 | 2.0 |
Cell Survival/drug effects | 3 | 0.0 |
Interleukin-2/biosynthesis | 2 | 0.0 |
Mitogen-Activated Protein Kinases/*metabolism | 2 | 0.0 |
Apoptosis/*drug effects/genetics | 2 | 6.0 |
Cell Death/drug effects | 3 | 1.0 |
Substrate Specificity | 2 | 0.0 |
Phenotype | 4 | 0.0 |
English Abstract | 2 | 0.0 |
Caspases/antagonists & inhibitors | 2 | 4.0 |
Antigens, CD95/genetics/*metabolism | 4 | 21.0 |
Molecular Weight | 4 | 0.0 |
Recombinant Fusion Proteins/metabolism | 5 | 0.0 |
RNA, Messenger/genetics/metabolism | 2 | 0.0 |
RNA, Messenger/genetics | 2 | 0.0 |
Caspases/*immunology | 2 | 66.0 |
Tumor Necrosis Factor-alpha/pharmacology/*physiology | 2 | 5.0 |
Caspases/*antagonists & inhibitors/*metabolism | 2 | 50.0 |
Viral Proteins/metabolism | 2 | 2.0 |
Peptide Library | 2 | 1.0 |
Apoptosis/genetics/*immunology | 2 | 11.0 |
Clone Cells | 2 | 0.0 |
Rats | 4 | 0.0 |
Staurosporine/pharmacology | 3 | 1.0 |
Peptides/chemistry | 2 | 0.0 |
Carrier Proteins/*biosynthesis | 2 | 3.0 |
Lymphoma, B-Cell/*metabolism/pathology | 2 | 13.0 |
Antigens, CD/*physiology | 4 | 1.0 |
*Proteins | 2 | 0.0 |
Receptors, Tumor Necrosis Factor/biosynthesis/metabolism | 2 | 33.0 |
Cytoplasm/metabolism | 5 | 0.0 |
*Drug Resistance, Neoplasm | 2 | 1.0 |
Transcription, Genetic/drug effects | 3 | 0.0 |
Membrane Glycoproteins/genetics | 3 | 1.0 |
B-Lymphocytes/metabolism | 2 | 1.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/*metabolism | 3 | 1.0 |
*Mitogen-Activated Protein Kinase Kinases | 2 | 2.0 |
*Mitogen-Activated Protein Kinases | 4 | 1.0 |
Plant Proteins/metabolism | 5 | 25.0 |
T-Lymphocytes/metabolism | 3 | 1.0 |
Antigens, CD/*metabolism | 3 | 0.0 |
Apoptosis/genetics/*physiology | 2 | 5.0 |
Dactinomycin/pharmacology | 2 | 0.0 |
Enzyme Precursors/*metabolism | 2 | 1.0 |
B-Lymphocytes/*physiology | 2 | 1.0 |
Mice, Transgenic | 3 | 0.0 |
Apoptosis/*genetics | 2 | 0.0 |
*Mutation | 2 | 0.0 |
Carrier Proteins/genetics/metabolism/*physiology | 2 | 12.0 |
*Ultraviolet Rays | 4 | 1.0 |
T-Lymphocytes/*metabolism | 3 | 0.0 |
Transfection/genetics | 3 | 2.0 |
Carrier Proteins/*genetics/metabolism | 2 | 0.0 |
Retroviridae/genetics | 5 | 1.0 |
Lymphocyte Activation/*physiology | 2 | 2.0 |
*Caspases | 10 | 17.0 |
Cysteine Endopeptidases/metabolism | 6 | 2.0 |
Cysteine Endopeptidases/*metabolism | 3 | 1.0 |
NF-kappa B/*physiology | 2 | 2.0 |
Caspase 1 | 3 | 7.0 |
Proteins/*physiology | 2 | 1.0 |
Sphingomyelin Phosphodiesterase/*metabolism | 2 | 11.0 |
Gene Expression/genetics | 2 | 0.0 |
Antibodies | 2 | 0.0 |
Sequence Analysis, DNA | 2 | 0.0 |
Cell Division | 4 | 0.0 |
Leukemia/*metabolism/pathology | 2 | 11.0 |
Receptors, Tumor Necrosis Factor | 3 | 1.0 |
Gene Deletion | 2 | 0.0 |
Enzyme Induction | 2 | 0.0 |
Protein Processing, Post-Translational | 2 | 0.0 |
Recombinant Proteins | 2 | 0.0 |
Receptors, Tumor Necrosis Factor/genetics/metabolism | 2 | 15.0 |
Tumor Necrosis Factor-alpha/physiology | 3 | 1.0 |
Magnetic Resonance Spectroscopy | 2 | 0.0 |
Promoter Regions (Genetics) | 2 | 0.0 |
NF-kappa B/physiology | 2 | 2.0 |
Trans-Activation (Genetics) | 3 | 0.0 |
*Lymphocyte Activation | 2 | 0.0 |
Neoplasm Proteins/metabolism | 4 | 1.0 |
Blotting, Western/methods | 2 | 1.0 |
*MAP Kinase Kinase Kinase 1 | 2 | 1.0 |
Cell Cycle/drug effects | 2 | 0.0 |
Protein Structure, Tertiary/physiology | 3 | 1.0 |
Cytochromes c/metabolism | 2 | 3.0 |
Arabidopsis Proteins/*metabolism | 2 | 66.0 |
Cell Division/physiology | 3 | 0.0 |
Caspases/metabolism/*physiology | 2 | 28.0 |
Phosphatidylserines/metabolism | 2 | 3.0 |
Etoposide/pharmacology | 2 | 1.0 |
Jurkat Cells/drug effects | 2 | 22.0 |
Endodeoxyribonucleases/metabolism | 2 | 6.0 |
Transduction, Genetic | 2 | 0.0 |
*DNA-Binding Proteins | 2 | 0.0 |
Receptors, Tumor Necrosis Factor, Type II | 2 | 0.0 |
